N-cyanopyrrolidine USP30 Inhibitors Mitochondrial Dysfunction

The patent employs parameter changes by systematically modifying the chemical structure of USP30 inhibitors (changing molecular parameters such as substituent groups, ring structures, and stereochemistry) to optimize the balance between efficacy and safety. This is evident in the extensive description of formula (I) variations and their differential effects on USP30 inhibition potency and selectivity, thereby improving therapeutic reliability while minimizing harmful effects.

The patent applies local quality by designing inhibitors with specific structural features targeted at particular regions of the USP30 enzyme active site. The detailed specification of substituent positions (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12) and their individual contributions to binding affinity and selectivity demonstrates how localized structural modifications enhance efficacy without compromising safety.

The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments (core pyrrolidine structure, oxazole/oxadiazole moiety, substituent groups R1-R12) that can be independently optimized. This modular approach allows systematic enhancement of potency through specific segment modifications while maintaining overall selectivity, as evidenced by the structure-activity relationship data presented for different substituent combinations.

The patent uses intermediary structures (specific substituent groups and linking moieties) that mediate between the core inhibitor structure and the USP30 binding site. These intermediary elements (such as the oxazole/oxadiazole ring system and various substituent patterns) facilitate high-affinity binding while providing a buffer that maintains selectivity, resolving the contradiction between potency and selectivity optimization.